Goal is to help pharmaceutical innovators evaluate opportunities earlier and accelerate future central nervous system pipelines

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it has signed an agreement for a research collaboration led by Alice Stanton, PhD from Massachusetts General Hospital (MGH) to advance the science of nose-to-brain (N2B) drug delivery.

Aptar and its collaborators will develop an integrated translational research platform combining in vitro, in vivo and computational technologies and evaluate a broad range of molecular classes and physicochemical properties to quantitatively characterize the mechanisms, pathways, and kinetics of nose-to-brain transport.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.